Role of Chk1 in the differentiation program of hematopoietic stem cells

• Published in: Cellular and molecular life sciences : CMLS 2010-05, Vol.67 (10), p.1713-1722
• Main Authors: Carrassa, Laura, Montelatici, Elisa, Lazzari, Lorenza, Zangrossi, Stefano, Simone, Matteo, Broggini, Massimo, Damia, Giovanna
• Format: Article
• Language: English
• Subjects: AC133 Antigen; Antigens, CD - metabolism; Antigens, Differentiation, Myelomonocytic - metabolism; Biochemistry; Biomedical and Life Sciences; Biomedicine; Blood; Cell Biology; Cell Death - drug effects; Cell Death - radiation effects; Cell Differentiation - drug effects; Cell Differentiation - radiation effects; Cell Proliferation - drug effects; Cell Proliferation - radiation effects; Cell Separation; Cellular biology; Checkpoint Kinase 1; DNA Damage; Fetal Blood - cytology; Gene expression; Gene Expression Regulation, Enzymologic - drug effects; Gene Expression Regulation, Enzymologic - radiation effects; Glycoproteins - metabolism; Hematopoietic Stem Cells - cytology; Hematopoietic Stem Cells - drug effects; Hematopoietic Stem Cells - enzymology; Hematopoietic Stem Cells - radiation effects; Humans; Infant, Newborn; Ionizing radiation; Kinetics; Life Sciences; Molecular biology; Peptides - metabolism; Protein Kinase Inhibitors - pharmacology; Protein Kinases - genetics; Protein Kinases - metabolism; Radiation, Ionizing; Research Article; RNA, Messenger - genetics; RNA, Messenger - metabolism; Sialic Acid Binding Ig-like Lectin 3; Signal transduction; Stem cells
• ISSN: 1420-682X; 1420-9071
• DOI: 10.1007/s00018-010-0274-1

Hematopoietic stem cells (HSC) isolated from umbilical cord blood (UCB) were treated with ionizing radiation (IR) and sensitivity and IR induced checkpoints activation were investigated. No difference in the sensitivity and in the activation of DNA damage pathways was observed between CD133+ HSC and cells derived from them after ex vivo expansion. Chk1 protein was very low in freshly isolated CD133+ cells, and undetectable in ex vivo expanded UCB CD133+ cells. Chk1 was expressed only on day 3 of the ex vivo expansion. This pattern of Chk1 expression was corroborated in CD133+ cells isolated from peripheral blood apheresis collected from an healthy donor. Treatment with a specific Chk1 inhibitor resulted in a strong reduction in the percentage of myeloid precursors (CD33+) and an increase in the percentage of lymphoid precursors (CD38+) compared to untreated cells, suggesting a possible role for Chk1 in the differentiation program of UCB CD133+ HSC.